Cynata Therapeutics Limited
CYYNF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.17 | 0.12 | -0.02 | 0.32 |
| FCF Yield | -35.20% | -19.44% | -27.33% | -5.30% |
| EV / EBITDA | -2.13 | -4.53 | -2.22 | -2.84 |
| Quality | ||||
| ROIC | -135.81% | -98.61% | -77.69% | -17.89% |
| Gross Margin | 100.00% | 87.88% | 83.08% | 96.40% |
| Cash Conversion Ratio | – | 1.02 | 1.00 | 0.61 |
| Growth | ||||
| Revenue 3-Year CAGR | 4.45% | -33.21% | 2.28% | 3.48% |
| Free Cash Flow Growth | 11.95% | 30.26% | -333.03% | 36.12% |
| Safety | ||||
| Net Debt / EBITDA | 0.54 | 0.62 | 0.99 | 1.76 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 20.26 | -543.69 | -1,625.13 | -2,055.81 |